Publication: Prevalence of human immunodeficiency virus-1 drugresistant mutations among adults on first- and second-line antiretroviral therapy in a resourcelimited health facility in Busia County, Kenya
Loading...
Files
Total Views 0
total viewsTotal Downloads 2
total downloadsDate
2020-12-03
Journal Title
Journal ISSN
Volume Title
Funder
NRF
Publisher
Cite this Item
Abstract
Introduction: in Kenya, about 1.5 million people are
living with the Human Immunodeficiency Virus
(HIV). Antiretroviral therapy aids in viral
suppression. However, drug-resistance threaten the
gains of the HIV infection control program. To
determine the prevalence of HIV-1 drug-resistant
mutations among adults on ARV therapy attending
Khunyangu sub-county hospital in Busia County,
Kenya, 50 blood samples were analyzed. Methods:
the samples were collected from November 2019 to
January 2020 and tested for HIV-1 viral load. HIV-1
drug-resistance was analyzed through the
sequencing of the HIV-1 pol gene. Generated
sequences were aligned using RECall (beta v3.05)
software. HIV-1 drug-resistance was determined
using the Stanford University HIV database.
Results: females were 34 and males 16. The general
prevalence of HIV-1 drug-resistance was 68%. Out
of 34 participants on first-line drugs, 59.9% had
mutations against these drugs and 5.9% against the
second-line drugs. Out of 16 participants on secondline drugs, 43.8% had mutations against these
drugs and 50% against the first-line drugs. The
prevalence of mutations encoding resistance to
Nucleotide reverse transcriptase inhibitors (NRTIs)
were 23(46%); Non-nucleotide Reverse
transcriptase inhibitors (NNRTIs), 29(58%) and
protease inhibitors (PIs), 7(14%). Dual and multiclass HIV-1 drug-resistance prevalence was as
follows: NRTIs + NNRTIs 16(32%); NRTIs + NNRTs +
PIs 4(8%); NRTIs + PIs 1(2%). A total of 126
mutations were identified. Predominant NNRTIs
mutations were K103N (15), Y181C (9), G190A (7),
and H221Y (6) NRTIs, M184V (17), Y115F (5) and PIs,
I54V (4). Conclusion: the study demonstrates a high
prevalence of HIV-1 drug-resistance which calls for
intervention for the strengthening of health
programs
